Merck has moved to strengthen its position in oncology and rare diseases with a $3.9bn agreement to acquire SpringWorks ...

The FDA has granted rare paediatric disease and orphan drug designations for IN013, Innorna's mRNA therapeutic for Wilson's ...

Amgen has announced a significant expansion of the Ohio manufacturing facility in the US, with an investment of $900m.

China’s NMPA has approved InnoCare Pharma’s orelabrutinib for use as a first-line treatment for CLL and small lymphocytic ...